Skip to content

Eastgate Biotech Corp: 10-Q filed 2017-03-09

What Eastgate Biotech Corp reported in its quarterly report filed 2017-03-09 (fiscal Q2 2016): 21 published measures, 63 facts as tagged in accession 0001640334-17-000446.

This filing

Form
10-Q (quarterly report)
Filed
2017-03-09
Fiscal period
fiscal Q2 2016
Accession
0001640334-17-000446 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Eastgate Biotech Corp filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-06-30764,520USD
At 2015-12-31297,919USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-06-303,829,951USD
At 2015-12-312,779,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-06-30-3,065,431USD
At 2015-12-31-2,481,081USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-06-3072,543USD
At 2015-12-3119,241USD
At 2014-12-31286,481USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-628,309USD91
2016-01-01 to 2016-06-30-1,326,021USD182
2015-04-01 to 2015-06-30-827,209USD91
2015-01-01 to 2015-06-30-2,619,859USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-06-30-12,979,538USD
At 2015-12-31-11,653,520USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-06-30157,298USD
At 2015-12-31184,402USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-586,907USD91
2016-01-01 to 2016-06-30-1,249,283USD182
2015-04-01 to 2015-06-30-800,506USD91
2015-01-01 to 2015-06-30-2,570,506USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-06-30607,222USD
At 2015-12-31113,517USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-04-01 to 2016-06-3041,402USD91
2016-01-01 to 2016-06-3076,738USD182
2015-04-01 to 2015-06-3026,703USD91
2015-01-01 to 2015-06-3049,353USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-06-303,781,860USD
At 2015-12-312,728,614USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-04-01 to 2016-06-30663,695USD91
2016-01-01 to 2016-06-301,327,156USD182
2015-04-01 to 2015-06-30850,619USD91
2015-01-01 to 2015-06-302,620,619USD181

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2016-04-01 to 2016-06-3076,788USD91
2016-01-01 to 2016-06-3077,873USD182
2015-04-01 to 2015-06-3050,113USD91
2015-01-01 to 2015-06-3050,113USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-04-01 to 2016-06-30115,130USD91
2016-01-01 to 2016-06-30251,552USD182
2015-04-01 to 2015-06-30297,858USD91
2015-01-01 to 2015-06-30693,978USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-06-30306,272,175shares
At 2015-12-31282,872,175shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2016-06-3020,034USD
At 2015-12-3131,846USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-628,309USD91
2016-01-01 to 2016-06-30-1,326,021USD182
2015-04-01 to 2015-06-30-827,209USD91
2015-01-01 to 2015-06-30-2,619,859USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-624,504USD91
2016-01-01 to 2016-06-30-1,337,833USD182
2015-04-01 to 2015-06-30-832,433USD91
2015-01-01 to 2015-06-30-2,625,171USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-30433,737USD91
2016-01-01 to 2016-06-30851,609USD182
2015-04-01 to 2015-06-30455,427USD91
2015-01-01 to 2015-06-301,509,702USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-41,402USD91
2016-01-01 to 2016-06-30-76,738USD182
2015-04-01 to 2015-06-30-26,703USD91
2015-01-01 to 2015-06-30-49,353USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-06-302,027USD182
2015-01-01 to 2015-06-3049,242USD181

Inspect the source

Entity
Eastgate Biotech Corp / CIK 0001099574
Captured
SEC response SHA-256
c76fb31ad9e6a591ce49245f912371413b5720c281a157c432746a7cf121003d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001099574.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))